PRESS RELEASE published on 04/29/2025 at 22:05, 1 year 4 months ago Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis Abivax completes enrollment for Phase 3 ABTECT Trials in patients with active ulcerative colitis. Top-line results expected in Q3 2025, NDA submission planned for H2 2026 Abivax Ulcerative Colitis Phase 3 ABTECT Trials NDA Submission
BRIEF published on 04/22/2025 at 22:10, 1 year 4 months ago Abivax: Terms of the Annual General Meeting and outlook for 2025 Biotechnology Abivax Clinical Trials Investment General Meeting 2025
BRIEF published on 04/22/2025 at 22:05, 1 year 4 months ago Abivax welcomes Dr. Dominik Höchli to its Board of Directors Board Of Directors Abivax Phase 3 Immunology Dominik Höchli
PRESS RELEASE published on 04/22/2025 at 22:05, 1 year 4 months ago Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax announces details of Annual General Meeting on June 6, 2025, in Paris as it progresses towards key 2025 milestones, including Phase 3 ABTECT trials Annual General Meeting Abivax Clinical-stage Biotechnology Phase 3 ABTECT Trials 2025 Milestones
PRESS RELEASE published on 04/22/2025 at 22:00, 1 year 4 months ago Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax appoints Dominik Höchli, MD to Board of Directors, bringing extensive immunology expertise ahead of key Phase 3 data readout in ulcerative colitis in Q3 2025 Board Of Directors Abivax Ulcerative Colitis Dominik Höchli Phase 3 Data Readout
BRIEF published on 04/18/2025 at 18:05, 1 year 4 months ago ABIVAX: Share Capital and Voting Rights as of March 31, 2025 Euronext Paris Share Capital Voting Rights Actions Abivax
BRIEF published on 04/18/2025 at 18:05, 1 year 4 months ago ABIVAX: Details of Share Capital and Voting Rights as of March 31, 2025 Euronext Paris Share Capital Voting Rights Biotechnology Abivax
BRIEF published on 03/27/2025 at 18:05, 1 year 5 months ago ABIVAX: Update of share capital and voting rights Share Capital Voting Rights Biotechnology AMF Abivax
BRIEF published on 03/26/2025 at 22:10, 1 year 5 months ago Abivax publishes its 2024 financial reports Biotechnology AMF Abivax Financial Reports DRY
PRESS RELEASE published on 03/26/2025 at 22:05, 1 year 5 months ago Abivax publishes financial reports with the French and U.S. securities regulatory agencies Abivax publishes financial reports with French and U.S. securities regulatory agencies. The company filed its Universal Registration Document and Annual Report for 2024 Abivax Financial Reports Regulatory Agencies U.S. Securities French
Published on 09/17/2026 at 12:00, 25 minutes ago Banyan Gold Intersects 1.05 g/t Gold over 52.8 metres and Bonanza-Grade Gold at Powerline Deposit, AurMac, Yukon, Canada
Published on 09/17/2026 at 10:00, 2 hours 25 minutes ago Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/16/2026 at 23:45, 12 hours 40 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 14 hours 55 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 19 hours 30 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/17/2026 at 12:15, 10 minutes ago BDStar Hosted 2026 Ecosystem Partner Conference in Munich, Germany
Published on 09/17/2026 at 11:30, 55 minutes ago EyeROV: Indian Deep-Tech Startup Showcases its Underwater Drones to World Leaders
Published on 09/17/2026 at 11:00, 1 hour 25 minutes ago ABB Ltd: ABB share buybacks - September 10, 2026 - September 16, 2026
Published on 09/16/2026 at 17:45, 18 hours 40 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 5 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 18 hours ago Report on the Combined General Meeting of the 10th of September 2026
